Focused On-demand Library for Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q969Q6

UPID:

P2R3C_HUMAN

Alternative names:

Protein phosphatase subunit G5PR; Rhabdomyosarcoma antigen MU-RMS-40.6A/6C

Alternative UPACC:

Q969Q6; B4DEN7; D3DS97; D3DS98; Q5GJ55; Q5GJ56; Q6P4G2; Q86TZ3; Q9NWR9

Background:

Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma, also known as Protein phosphatase subunit G5PR and Rhabdomyosarcoma antigen MU-RMS-40.6A/6C, plays a pivotal role in various cellular processes. It is involved in the regulation of MCM3AP phosphorylation, acts as a negative regulator of ABCB1 expression and function, and may contribute to the activation-induced cell death of B-cells. This protein's multifaceted role in biological systems makes it an intriguing subject for scientific inquiry.

Therapeutic significance:

Linked to Myoectodermal gonadal dysgenesis syndrome and Spermatogenic failure 36, Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma's involvement in these diseases highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies, offering hope for patients suffering from these conditions.